Rebus Holdings Inc (PK)
0.00 (0.00%)


Draw Mode:

Volume 800
Bid Price 0.0075
Ask Price 0.0105
News -
Day High 0.009


52 Week Range


Day Low 0.0075
Company Name Stock Ticker Symbol Market Type
Rebus Holdings Inc (PK) RBSH OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.0075 11:19:58
Open Price Low Price High Price Close Price Prev Close
0.009 0.0075 0.009 0.0075 0.0075
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2 800 $ 0.007763 $ 6 - 0.005 - 0.0278
Last Trade Time Type Quantity Stock Price Currency
11:19:58 660 $ 0.0075 USD

Rebus Holdings Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 241.00k 32.13M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
25.53k $ - - - -

more financials information »

Rebus (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RBSH Message Board. Create One! See More Posts on RBSH Message Board See More Message Board Posts

Historical RBSH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.01010.01450.00750.014056311,052-0.0026-25.74%
1 Month0.010.01450.00620.008589458,888-0.0025-25.0%
3 Months0.0080.01450.00550.009658555,898-0.0005-6.25%
6 Months0.0170.02440.0050.011349351,143-0.0095-55.88%
1 Year0.010.02780.0050.0145749123,143-0.0025-25.0%
3 Years0.09990.120.0050.0253146349,642-0.0924-92.49%
5 Years0.09990.120.0050.0253146349,642-0.0924-92.49%

Rebus (PK) Description

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.